Could HLA typing be the missing link in your precision oncology strategy?
During this webinar, we will take you along in their recent experiences about HLA Typing and Precision Medicine for Oncology Immunotherapy.
Stephanie Ahrendt, International Medical Science Liaison Manager at Eurobio Scientific will explore how oncology has evolved from broad treatments to highly personalized care. She will discuss the challenge of tumour heterogeneity and the growing role of biomarkers—like TAAs and TSAs,—in guiding treatment. She will also highlight how HLA polymorphisms are emerging as key predictors of immunotherapy success, and how immunotherapy is helping target cancers that evade immune detection.
Valentina Manzini, Project Coordinator Companion Diagnostics at GenDx, will introduce the fundamentals of HLA biology and its role in immune recognition. She will explain how HLA typing has advanced—from serology to NGS—and how it’s enabling HLA-restricted therapies like cancer vaccines and adoptive T-cell treatments. Using real-world examples, she will show how HLA typing is becoming a companion diagnostic and shaping the future of personalized immunotherapy.